Thursday 16 October, 2025
Introduction: Compared to overall survival, progression free survival (PFS) requires a shorter follow-up and can analyze the efficacy of therapy…
Read morePoster: Drug/Disease Modelling - Oncology
A semi-mechanistic model of preclinical VSV-GP(-Luc) viral dynamics in blood and tumour
Thursday 16 October, 2025
Introduction/Objectives: Despite recent advancements in cancer treatment, cancer remains a leading cause of death globally [1,2], highlighting the need for…
Read moreA semi-mechanistic model to describe preclinical tumour viral dynamics of an oncolytic virus
Thursday 16 October, 2025
Introduction/Objectives: Although cancer treatment is continuously improving, cancer is still one of the leading causes of death worldwide, accounting for…
Read moreHow to handle non-linearity in absorption: a case study in oncology
Thursday 16 October, 2025
Objectives: Drug S is an orally administered compound, with a complex absorption due to a low solubility, currently in clinical development…
Read morePopulation pharmacokinetic analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugate
Thursday 16 October, 2025
Introduction/objectives Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) in clinical development for the…
Read moreJoint Modeling Of Longitudinal Circulating Tumor DNA And Survival In Metastatic Colorectal Cancer: A Promise Of Early Prediction Of Response In Oncology?
Thursday 16 October, 2025
Introduction: Circulating tumor DNA (ctDNA) is shed from tumors and present in blood of patients with cancer. Compared with tumor…
Read moreInvestigating the PK/PD relationship of a new pro-apoptotic drug through tumor growth inhibition modelling in NUDE rats
Thursday 16 October, 2025
Objectives: Apoptosis is the process of programmed cell death that tumor cells escape. Drug S is a pro-apoptotic compound in preclinical…
Read moreExposure-response relationships of the efficacy and safety of apalutamide (APA) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
Thursday 16 October, 2025
Objectives: Apalutamide (APA; ERLEADA®), an orally administered selective androgen receptor inhibitor,1 is approved for the treatment of men with non-metastatic…
Read moreMulti-state modeling and simulation of patient trajectories after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to inform drug development
Thursday 16 October, 2025
Objectives: To characterize patient trajectories through states of disease after allo-HSCT, quantifying the transition rates into various event states and…
Read moreModeling Primary Tumor Growth in a Xenograft Mouse Model of Non-Small Cell Lung Cancer Treated With Pemetrexed-Cisplatin and Bevacizumab
Thursday 16 October, 2025
Objectives: Bevacizumab, an anti-angiogenic drug, is commonly administered along with chemotherapeutic drugs for advanced non-squamous non-small cell lung cancer (NSCLC)…
Read more